Back to Search Start Over

Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection

Authors :
José Luís Passos-Coelho
S Sousa
J Antas
M. G. Da Silva
P. Pimentel
Alzira Carvalhais
Isabela Marim Barbosa
A Campos
F. Leal da Costa
A. Machado
Carlos Pinho Vaz
Fernando Campilho
Nuno Miranda
Source :
Bone marrow transplantation. 34(8)
Publication Year :
2004

Abstract

Up to a third of autologous transplantation candidates fail to mobilize hematopoietic progenitors into the peripheral blood with chemotherapy and/or growth factor treatment, thus requiring innovative mobilization strategies. In total, 20 cancer patients unable to provide adequate PBPC products after a previous mobilization attempt were treated with ancestim (20 microg/kg/day s.c.) and filgrastim (10 microg/kg/day s.c.). In 16 patients, the pre-study mobilization was with filgrastim alone. Eight patients underwent single large volume leukapheresis (LVL) and 12 multiple standard volume leukaphereses (SVL) in both mobilizations. Pairwise comparison of peripheral blood CD34(+) cell concentrations on the day of first leukapheresis failed to document synergism - median CD34(+)/microl of 3.2 (

Details

ISSN :
02683369
Volume :
34
Issue :
8
Database :
OpenAIRE
Journal :
Bone marrow transplantation
Accession number :
edsair.doi.dedup.....c9a73086f951ec6a385a362822e8e363